# Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients

> **NCT00254787** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** IR (Immediate-Release) quetiapine fumarate (drug)

## Key facts

- **NCT ID:** NCT00254787
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 30 (—)
- **Last updated:** 2009-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254787, "Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00254787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*